AC-TH regimen: Cyclophosphamide 600 mg/m^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).

AC-TH regimen: Docetaxel 100 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).

Participants will receive Doxorubicin 60 mg/m^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.

AC-TH regimen: Paclitaxel 175 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).

AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.

Overall survival was defined as time from the date of first study treatment until date of death, regardless of the cause of death.

Participants received trastuzumab with TCH regimen. The choice of the regimen was based on the investigator's discretion referring the local prescribing document of trastuzumab. TCH consisted of docetaxel and carboplatin. Trastuzumab was common in both treatment regimens and was administered weekly or every 3 weeks, as per investigator discretion. Each cycle was 3 weeks.

Total of all reporting groups

Participants received trastuzumab with TCH regimen. The choice of the regimen was based on the investigator's discretion referring the local prescribing document of trastuzumab. TCH consisted of docetaxel and carboplatin. Trastuzumab was common in both treatment regimens and was administered weekly or every 3 weeks, as per investigator discretion. Each cycle was 3 weeks.

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events.

Safety Population included all enrolled participants who received at least one dose of study medication.

DFS was defined as time from the date of first study treatment to the date of local, regional or distant recurrence, contra-lateral breast cancer or death due to any cause. Local, regional or distant recurrence, and contra-lateral breast cancer was assessed by combination of physical examination, mammography and pelvic examination.

ITT population included all participants enrolled in the study.

Overall survival was defined as time from the date of first study treatment until date of death, regardless of the cause of death.

ITT population included all participants enrolled in the study.

Participants received trastuzumab with TCH regimen. The choice of the regimen was based on the investigator's discretion referring the local prescribing document of trastuzumab. TCH consisted of docetaxel and carboplatin. Trastuzumab was common in both treatment regimens and was administered weekly or every 3 weeks, as per investigator discretion. Each cycle was 3 weeks.